Costotransverse Foramen Block With Erector Spinae Plane Block in Modified Radical Mastectomy

National Cancer Institute, Egypt

Status: Enrolling

Conditions: Erector Spinae Plane Block; Costotransverse Foramen Block; Modified Radical Mastectomy

Treatments: Other: Erector spinae plane block; Other: Costotransverse foramen block

Study type: Interventional

Funder types: Other

Identifiers

NCT07367568

AP2509-501-124-203

Details and patient eligibility

About

This study aims to compare the costotransverse foramen block with erector spinae plane block in modified radical mastectomy.

Full description

Postoperative pain following modified radical mastectomy (MRM) is a considerable consequence, impacting the ipsilateral upper limbs, axillae, and thorax, resulting in diminished functional ability and substantial economic and societal repercussions.

Erector spinae plane block (ESPB), an interfascial block, minimizes nerve and vessel injury by allowing local anesthetics to diffuse across relevant spaces; it is technically simpler and has shown benefits in reducing postoperative analgesic use and pain scores.

A novel technique, the costotransverse foramen block (CTFB), is one type of Inter-transverse process (ITP) blocks. This technique entails the anterior dispersion of the local anesthetic injectate into the paravertebral region, affecting the thoracic nerve at the injection site and neighboring levels, while exhibiting negligible posterior diffusion of dye to the deep back muscles

Enrollment: 110 estimated patients

Sex: Female

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult females > 18 years and ≤ 65 years old.
• American Society of Anesthesiologists (ASA) physical status П-III.
• Body mass index (BMI) 18-35 kg/m2.
• Scheduled for modified radical mastectomy.

Exclusion criteria

• Known allergy or hypersensitivity to local anesthetic agents.
• Active infection at the injection site (e.g., cellulitis, abscess).
• Coagulopathy or ongoing anticoagulant/antiplatelet therapy [International Normalized Ratio (INR) > 1.5 or platelet count < 100,000/µL].
• Severe respiratory, cardiac, hepatic, or renal disease.
• Morbid obesity.
• Severe cognitive impairment or uncooperative behavior that could interfere with block placement.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

110 participants in 2 patient groups

CTFB Group

Experimental group

Description:

Patients will receive an ipsilateral ultrasound-guided costotransverse foramen block with injection of 20 ml bupivacaine 0.25%.

Treatment:

Other: Costotransverse foramen block

ESPB Group

Experimental group

Description:

Patients will receive an ipsilateral ultrasound-guided erector spinae plane block with injection of 20 ml bupivacaine 0.25%.

Treatment:

Other: Erector spinae plane block